Impact of metabolic dysfunction on cognition in humans.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
6
12
2020
medline:
15
12
2021
entrez:
5
12
2020
Statut:
ppublish
Résumé
The current review evaluates the recent literature on the impact of metabolic dysfunction in human cognition, focusing on epidemiological studies and meta-analyses of these. Worldwide around 50 million people live with dementia, a number projected to triple by 2050. Recent reports from the Lancet Commission suggest that 40% of dementia cases may be preventable primarily by focusing on well established metabolic dysfunction components and cardiovascular risk factors. There is robust evidence that type 2 diabetes and midlife hypertension increase risk of dementia in late life. Obesity and elevated levels of LDL cholesterol in midlife probably increase risk of dementia, but further research is needed in these areas. Physical activity, diet, alcohol, and smoking might also influence the risk of dementia through their effect on metabolic dysfunction. A key recommendation is to be ambitious about prevention, focusing on interventions to promote healthier lifestyles combating metabolic dysfunction. Only comprehensive multidomain and staff-requiring interventions are however efficient to maintain or improve cognition in at-risk individuals and will be unrealistic economic burdens for most societies to implement. Therefore, a risk score that identifies high-risk individuals will enable a targeted early intensive intervention toward those high-risk individuals that will benefit the most from a prevention against cardiovascular risk factors and metabolic dysfunction.
Identifiants
pubmed: 33278082
pii: 00041433-202102000-00007
doi: 10.1097/MOL.0000000000000723
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-61Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020; 396:413–446.
Nichols E, Szoeke CEI, Vollset SE, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18:88–106.
Patterson C. World Alzheimer Report 2018: the state of the art of dementia research: new frontiers. London Alzheimers Dis Int 2018; https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf
World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. Geneva: World Health Organisation; 2019.
Alzheimer's Association. 2019 Alzheimer's disease facts and figures. Alzheimers Dement 2019; 15:321–387.
Yaffe K. Prevention of cognitive impairment with intensive systolic blood pressure control. JAMA 2019; 321:548–549.
Norton S, Matthews FE, Barnes DE, et al. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 2014; 13:788–794.
Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 2017; 14:577–599.
World Health Organization. Global report on diabetes. Geneva: World Health Organisation; 2016.
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157:107843.
Ott A, Stolk RP, Van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53:1937–1942.
Chatterjee S, Peters SAE, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 2016; 39:300–307.
Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig 2013; 4:640–650.
Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes – systematic overview of prospective observational studies. Diabetologia 2005; 48:2460–2469.
Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multisystem aging phenotypes: a systematic review and meta-analysis. PLoS One 2009; 4:e4144.
Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67:505–512.
Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. Epidemiol Psychiatr Sci 2020; 29:1–11.
Abner EL, Nelson PT, Kryscio RJ, et al. Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement 2016; 12:882–889.
Pruzin JJ, Schneider JA, Capuano AW, et al. Diabetes, hemoglobin A1c, and regional Alzheimer disease and infarct pathology. Alzheimer Dis Assoc Disord 2017; 31:41–47.
Javanshiri K, Waldö ML, Friberg N, et al. Atherosclerosis, hypertension, and diabetes in Alzheimer's disease, vascular dementia, and mixed dementia: prevalence and presentation. J Alzheimers Dis 2018; 65:1247–1258.
Kellar D, Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol 2020; 19:758–766.
Barrett EJ, Liu Z, Khamaisi M, et al. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab 2017; 102:4343–4410.
Moran C, Beare R, Phan T, et al. Neuroimaging and its relevance to understanding pathways linking diabetes and cognitive dysfunction. J Alzheimers Dis 2017; 59:405–419.
Benn M, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals. Diabetologia 2020; 63:1151–1161.
Larsson SC, Traylor M, Malik R, et al. Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis. BMJ 2017; 359:j5375.
Østergaard SD, Mukherjee S, Sharp SJ, et al. Associations between potentially modifiable risk factors and Alzheimer disease: a Mendelian randomization study. PLoS Med 2015; 12:e1001841.
Walter S, Marden JR, Kubzansky LD, et al. Diabetic phenotypes and late-life dementia risk: a mechanism-specific Mendelian randomization study. Alzheimer Dis Assoc Disord 2016; 30:15–20.
Dos Santos Matioli MNP, Suemoto CK, Rodriguez RD, et al. Diabetes is not associated with Alzheimer's disease neuropathology. J Alzheimers Dis 2017; 60:1035–1043.
Biessels GJ, Nobili F, Teunissen CE, et al. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurol 2020; 19:699–710.
Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018; 14:168–181.
Avgerinos KI, Kalaitzidis G, Malli A, et al. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review. J Neurol 2018; 265:1497–1510.
Kullmann S, Kleinridders A, Small DM, et al. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol 2020; 8:524–534.
Srikanth V, Sinclair AJ, Hill-Briggs F, et al. Type 2 diabetes and cognitive dysfunction – towards effective management of both comorbidities. Lancet Diabetes Endocrinol 2020; 8:535–545.
McMillan JM, Mele BS, Hogan DB, Leung AA. Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. BMJ Open Diabetes Res Care 2018; 6:1–12.
Areosa Sastre A, Vernooij RWM, González-Colaço Harmand M, Martínez G. Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2017. CD003804.
Craft S, Raman R, Chow TW, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol 2020; 77:1099–1109.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41:255–323.
Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019; 15:288–298.
Bentham J, Di Cesare M, Bilano V, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017; 390:2627–2642.
Albanese E, Launer LJ, Egger M, et al. Body mass index in midlife and dementia: systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. Alzheimers Dement (Amst) 2017; 8:165–178.
Pedditizi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. Age Ageing 2016; 45:14–21.
Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011; 12:e426–e437.
Singh-Manoux A, Dugravot A, Shipley M, et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. Alzheimers Dement 2018; 14:178–186.
Lee CMY, Woodward M, Batty GD, et al. Association of anthropometry and weight change with risk of dementia and its major subtypes: a meta-analysis consisting 2.8 million adults with 57 294 cases of dementia. Obes Rev 2020; 21:e12989.
Qizilbash N, Gregson J, Johnson ME, et al. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol 2015; 3:431–436.
Nordestgaard LT, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Body mass index and risk of Alzheimer's disease: a Mendelian randomization study of 399,536 individuals. J Clin Endocrinol Metab 2017; 102:2310–2320.
Luchsinger JA, Gustafson DR. Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care 2009; 12:15–21.
Kivimäki M, Singh-Manoux A, Shipley MJ, Elbaz A. Does midlife obesity really lower dementia risk? Lancet Diabetes Endocrinol 2015; 3:498.
LeBlanc ES, Rizzo JH, Pedula KL, et al. Weight trajectory over 20 years and likelihood of mild cognitive impairment or dementia among older women. J Am Geriatr Soc 2017; 65:511–519.
Ikeda M, Brown J, Holland AJ, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 73:371–376.
Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003–2013: a decade of body mass index, Alzheimer's disease, and dementia. J Alzheimers Dis 2015; 43:739–755.
Romo ML, Schooling CM. Examining the causal role of leptin in Alzheimer disease: a Mendelian randomization study. Neuroendocrinology 2017; 105:182–188.
Mukherjee S, Walter S, Kauwe JSK, et al. Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimers Dement 2015; 11:1439–1451.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019. 1–78. PMID: 31591002.
Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015; 116:665–673.
Juul Rasmussen I, Rasmussen KL, Nordestgaard BG, et al. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. Eur Heart J 2020; ehaa695. doi:10.1093/eurheartj/ehaa695. Online ahead of print.
doi: 10.1093/eurheartj/ehaa695.
Pase MP, Beiser A, Enserro D, et al. Association of ideal cardiovascular health with vascular brain injury and incident dementia. Stroke 2016; 47:1201–1206.
McGrath ER, Seshadri S. Author response: blood pressure from mid- to late life and risk of incident dementia. Neurology 2017; 89:2447–2454.
Abell JG, Kivimäki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J 2018; 39:3119–3125.
Lane CA, Barnes J, Nicholas JM, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol 2019; 18:942–952.
Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol 2020; 19:61–70.
Tully PJ, Hanon O, Cosh S, Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. J Hypertens 2016; 34:1027–1035.
Peters R, Yasar S, Anderson CS, et al. An investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology 2020; 94:1–15.
Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA 2019; 321:553–561.
Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years a randomized clinical trial. JAMA 2016; 315:2673–2682.
Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008; 16:343–354.
Anstey KJ, Ee N, Eramudugolla R, et al. A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence. J Alzheimers Dis 2019; 70:S165–S186.
McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2016. CD003160.
van der Lee SJ, Teunissen CE, Pool R, et al. Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies. Alzheimers Dement 2018; 14:707–722.
Tynkkynen J, Hernesniemi JA, Laatikainen T, et al. Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer's disease: the National Finnish population study (FINRISK). Age 2016; 38:465–473.
Tynkkynen J, Chouraki V, van der Lee SJ, et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: a prospective study in eight cohorts. Alzheimers Dement 2018; 14:723–733.
Proitsi P, Lupton MK, Velayudhan L, et al. Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis. PLoS Med 2014; 11:e1001713.
Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ 2017; 357:j1648.
Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105,949 individuals from a white general population cohort. Eur Heart J 2019; 40:2813–2824.
Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol 2020; 8:50–67.
Wellington CL, Frikke-Schmidt R. Relation between plasma and brain lipids. Curr Opin Lipidol 2016; 27:225–232.
Wolters FJ, Koudstaal PJ, Hofman A, et al. Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: the Rotterdam study. Neurosci Lett 2016; 617:139–142.
Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma apolipoprotein E levels and risk of dementia: a Mendelian randomization study of 106,562 individuals. Alzheimers Dement 2018; 14:71–80.
Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol 2015; 77:301–311.
Kivimäki M, Singh-Manoux A, Pentti J, et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ 2019; 365:l1495.
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017; 390:2673–2734.
Sabia S, Dugravot A, Dartigues JF, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. BMJ 2017; 357:1–12.
Zotcheva E, Bergh S, Selbæk G, et al. Midlife physical activity, psychological distress, and dementia risk: the HUNT study. J Alzheimers Dis 2018; 66:825–833.
Hersi M, Irvine B, Gupta P, et al. Risk factors associated with the onset and progression of Alzheimer's disease: a systematic review of the evidence. Neurotoxicology 2017; 61:143–187.
Akbaraly TN, Singh-Manoux A, Dugravot A, et al. Association of midlife diet with subsequent risk for dementia. JAMA 2019; 321:957–968.
Sabia S, Fayosse A, Dumurgier J, et al. Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study. BMJ 2018; 362:k2927.
Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ 2017; 357:j2353.
Ilomaki J, Jokanovic N, Tan ECK, Lonnroos E. Alcohol consumption, dementia and cognitive decline: an overview of systematic reviews. Curr Clin Pharmacol 2015; 10:204–212.
Choi D, Choi S, Park SM. Effect of smoking cessation on the risk of dementia: a longitudinal study. Ann Clin Transl Neurol 2018; 5:1192–1199.
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385:2255–2263.
Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement 2018; 14:263–270.
Coley N, Ngandu T, Lehtisalo J, et al. Adherence to multidomain interventions for dementia prevention: data from the FINGER and MAPT trials. Alzheimers Dement 2019; 15:729–741.